Immune Microenvironment and Immunotherapies for Diffuse Intrinsic Pontine Glioma.
Immune Microenvironment and Immunotherapies for Diffuse Intrinsic Pontine Glioma.
复制标题
作者：
弥漫性固有脑桥胶质瘤（DIPG）是一种恶性原发性神经胶质肿瘤，发生于所有年龄组，但以儿童为主，估计约占儿童脑肿瘤的10-15%。诊断时的中位年龄为6-7岁，儿童的中位生存期小于12个月。目前临床上尚无针对DIPG的有效治疗方法。免疫治疗的不断进步为DIPG的治疗带来了新的前景。本文就DIPG的免疫特性及现有的临床试验结果进行综述，希望对DIPG治疗的新型免疫疗法的发展有所帮助。弥漫性固有脑桥胶质瘤（DIPG）是一种原发性神经胶质瘤，发生于所有年龄组，但以儿童为主，是实体瘤相关儿童死亡率的主要原因。由于其进展迅速，不能手术，对大多数化疗不敏感，临床实践中缺乏有效的治疗方法。DIPG患者预后极差，中位生存期不超过12个月。近年来，各种血液肿瘤和预后极差的恶性实体瘤的免疫治疗不断取得突破，为缺乏有效治疗策略的肿瘤提供了新的认识。同时，随着立体定向活检技术的逐步发展，获得DIPG活组织逐渐变得更加容易和安全，对DIPG免疫特性的了解也在不断增加。在此基础上，一系列DIPG的免疫治疗研究正在进行中，其中一些研究显示出令人鼓舞的结果。在此，我们回顾了目前对DIPG免疫特性的认识，批判性地揭示了当前免疫研究的局限性，以及DIPG免疫治疗的机遇和挑战，希望能够阐明新的免疫治疗方法的发展。
Diffuse intrinsic pontine glioma (DIPG) is a malignant primary glial tumor that occurs in all age groups but predominates in children and is estimated to account for approximately 10–15% of pediatric brain tumors. The median age at diagnosis was 6–7 years, and the median survival of children is less than 12 months. At present, there is no effective treatment method for DIPG in the clinic. The continuous progress in immunotherapy has brought new prospects for the treatment of DIPG. In this review, we summarize the knowledge about the immune profile in DIPG and existing clinical trial results of DIPG, hoping to clarify the development of novel immunotherapies for DIPG treatment. Diffuse intrinsic pontine glioma (DIPG) is a primary glial glioma that occurs in all age groups but predominates in children and is the main cause of solid tumor-related childhood mortality. Due to its rapid progression, the inability to operate and insensitivity to most chemotherapies, there is a lack of effective treatment methods in clinical practice for DIPG patients. The prognosis of DIPG patients is extremely poor, with a median survival time of no more than 12 months. In recent years, there have been continuous breakthroughs for immunotherapies in various hematological tumors and malignant solid tumors with extremely poor prognoses, which provides new insights into tumors without effective treatment strategies. Meanwhile, with the gradual development of stereotactic biopsy techniques, it is gradually becoming easier and safer to obtain live DIPG tissue, and the understanding of the immune properties of DIPG has also increased. On this basis, a series of immunotherapy studies of DIPG are under way, some of which have shown encouraging results. Herein, we review the current understanding of the immune characteristics of DIPG and critically reveal the limitations of current immune research, as well as the opportunities and challenges for immunological therapies in DIPG, hoping to clarify the development of novel immunotherapies for DIPG treatment.
登录
查看更多内容
影响因子：
12.4
作者：
Ahmed, Atique U.;Rolle, Cleo E.;Lesniak, Maciej S.
通讯作者：
Lesniak, Maciej S.
DOI：
10.1016/j.omto.2017.04.002
发表时间：
2017-06-16
期刊：
Molecular therapy oncolytics
影响因子：
--
作者：
Cockle JV;Brüning-Richardson A;Scott KJ;Thompson J;Kottke T;Morrison E;Ismail A;Carcaboso AM;Rose A;Selby P;Conner J;Picton S;Short S;Vile R;Melcher A;Ilett E
通讯作者：
Ilett E
影响因子：
10.5
作者：
Chan, Kui-Ming;Fang, Dong;Zhang, Zhiguo
通讯作者：
Zhang, Zhiguo
影响因子：
10.1
作者：
Bockmayr, Michael;Klauschen, Frederick;Mohme, Malte
通讯作者：
Mohme, Malte
影响因子：
6.4
作者：
Grauer, Oliver M.;Sutmuller, Roger P. M.;Adema, Gosse J.
通讯作者：
Adema, Gosse J.